购物车
- 全部删除
- 您的购物车当前为空
CKI-7 free base is a potent and ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.
CKI-7 free base is a potent and ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
2 mg | ¥ 888 | 5日内发货 | |
50 mg | ¥ 5,190 | 1-2周 | |
100 mg | ¥ 9,320 | 1-2周 | |
1 mL x 10 mM (in DMSO) | ¥ 1,280 | 1-2周 |
产品描述 | CKI-7 free base is a potent and ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1), and MSK1. |
靶点活性 | CK1:6 μM, CK1:8.5 μM (ki) |
体外活性 | The treatment of CKI-7 (0.1-10 μM; 5 days; ES cells) significantly increases the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers βIII-tubulin and nestin, in a concentration-dependent manner. CKI-7 (5 μM; 5 days; ES cells) treatment suppresses SFEB-induced β-catenin stabilization on day 5 [1]. |
体内活性 | In vivo dose-dependent, the anti-tumor activity of CKI-7 is demonstrated in a SCID-Beige mouse systemic tumor model utilizing isolated Philadelphia chromosome-positive acute lymphoblastic leukemia cell line. Exposure to CKI-7 results in a cell cycle-dependent caspase 3 activation and apoptotic cell death [2]. |
别名 | CKI-7 |
分子量 | 285.75 |
分子式 | C11H12ClN3O2S |
CAS No. | 120615-25-0 |
密度 | 1.31g/cm3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 25 mg/mL (87.49 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容